Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil in multiple sclerosis.

Elliot M Frohman1, Kristen Brannon, Michael K Racke

  • 1Department of Neurology, University of Texas, Southwestern Medical Center at Dallas, USA. elliot.frohman@utsouthwestern.edu

Clinical Neuropharmacology
|July 15, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ImmuSeeker: deep mining of immune-related gene family signatures through lineage reconstruction.

Genome biology·2026
Same author

Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer's disease pathology.

The journal of prevention of Alzheimer's disease·2026
Same author

Clinical Manifestations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology.

Neurology. Clinical practice·2025
Same author

Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathology.

medRxiv : the preprint server for health sciences·2025
Same author

Correction: K27-linked RORγt ubiquitination by Nedd4 potentiates Th17-mediated autoimmunity.

Journal of biomedical science·2025

Mycophenolate mofetil (MMF) showed good tolerability in multiple sclerosis (MS) patients. Many experienced stable or improved MS disease course, suggesting MMF as a potential treatment option.

Area of Science:

  • Immunology
  • Neurology

Background:

  • Mycophenolate mofetil (MMF) is an immunosuppressant targeting purine synthesis in lymphocytes and macrophages.
  • It acts as a selective inhibitor of inosine 5'-monophosphate dehydrogenase type II.

Purpose of the Study:

  • To evaluate the clinical experience of using mycophenolate mofetil (MMF) for treating multiple sclerosis (MS).

Main Methods:

  • Retrospective review of 79 multiple sclerosis patients treated with MMF.
  • Patients included secondary progressive, relapsing-remitting, and primary progressive MS subtypes.
  • MMF was used as monotherapy or adjunctive treatment with interferon-beta or glatiramer acetate.

Main Results:

  • 70% of patients continued MMF therapy.

Related Experiment Videos

  • Common reasons for discontinuation included side effects (8 patients) and disease progression (7 patients).
  • One patient experienced transient hepatic transaminase elevation, and another had cytomegalovirus diarrhea.

    • Conclusions:

    • MMF was generally well-tolerated in the majority of multiple sclerosis patients.
    • Clinical course remained unchanged or subjectively improved in many patients.
    • Further randomized controlled trials of MMF in MS are warranted.